Kyntra Bio Scraps FG-3246 Phase 2 Trial, Posts $0.2M Q3 Profit
KYNB is trading near its 52-week low of $3.02 (6.0% above the low) on elevated volume (2.1× avg).
Summary
Kyntra Bio is killing its FG-3246 CD46 ADC program after a pre-specified interim analysis showed efficacy below the bar needed to continue; enrollment closes and all future investment is cancelled. Management expects that to save over $20 million in 2027 and 2028. The remaining story is roxadustat in LR-MDS, but the pivotal Phase 3 trial won't start until Q1 2027 and only if the company lands a strategic partnership or raises outside capital. Q3 revenue was $1.8 million versus $1.1 million a year ago, and net income from continuing operations was $0.2 million, or $0.04 a share, helped by a $14.0 million gain on debt restructuring. Cash, equivalents, investments and receivables totaled $44.1 million at September 30, which they say funds operations into 2028. The company also cut its maximum royalty obligation to NQ Project Phoebus by $60 million to $65 million, with only $15 million in future payments remaining after a $42.6 million accelerated payment. The delisting determination from Nasdaq in October remains an overhang on the stock.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Kyntra Bio cut its maximum royalty obligation to NQ Project Phoebus by $60 million to $65 million, with only $15 million in future payments remaining after a $42.6 million accelerated payment.
At the time of this announcement, KYNB was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $3.02 to $10.47. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.